High-dose toremifene as first-line treatment of metastatic breast cancer resistant to adjuvant aromatase inhibitor: A multicenter phase ii study

Oncology Letters

Volumn 3, Issue 1, 2012, Pages 61-65

  Sawaki, Masataka ^a   Wada, Masaki ^b   Sato, Yasuyuki ^c   Mizuno, Yutaka ^d   Kobayashi, Hironobu ^a   Yokoi, Kazuki ^e   Yoshihara, Motoi ^f   Kamei, Keitaro ^g   Ohno, Mototsugu ^h   Imai, Tsuneo ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Department of Surgery   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^d FUJITA HEALTH UNIVERSITY   (Japan)

^e Okazaki City Hospital   (Japan)

^f TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^g OGAKI MUNICIPAL HOSPITAL   (Japan)

^h GIFU PREFECTURAL TAJIMI HOSPITAL   (Japan)

Author keywords

Aromatase inhibitor resistant; Breast cancer; Toremifene

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; AROMACIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXEMESTANE; TAXANE DERIVATIVE; TOREMIFENE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOCALCEMIA; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84855210874     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.449     Document Type: Article

References (24)

1. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG and Sahmoud T: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131-2139, 2002.
2. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY and Tobias JS: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365: 60-62, 2005.
3. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, et al: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353: 2747-2757, 2005.
4. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, et al: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23: 619-629, 2005.
5. Thurlimann B, Robertson JF, Nabholtz JM, Buzdar A and Bonneterre J: Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 39: 2310-2317, 2003.
6. Lonning PE, Bajetta E, Murray R, Tubiana-Hulin M, Eisenberg PD, Mickiewicz E, Celio L, Pitt P, Mita M, Aaronson NK, et al: Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 18: 2234-2244, 2000.
7. Ingle JN, Suman VJ, Rowland KM, Mirchandani D, Bernath AM, Camoriano JK, Fishkin PA, Nikcevich DA and Perez EA: Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 24: 1052-1056, 2006.
8. Perey L, Paridaens R, Hawle H, Zaman K, Nole F, Wildiers H, Fiche M, Dietrich D, Clement P, Koberle D, et al: Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 18: 64-69, 2007.
9. Lonning PE: Additive endocrine therapy for advanced breast cancer - back to the future. Acta Oncol 48: 1092-1101, 2009.
10. Lewis JD, Chagpar AB, Shaughnessy EA, Nurko J, McMasters K and Edwards MJ: Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer. Cancer 116: 2307-2315, 2010.
11. Pyrhonen S, Ellmen J, Vuorinen J, Gershanovich M, Tominaga T, Kaufmann M and Hayes DF: Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat 56: 133-143, 1999.
12. Gams R: Phase III trials of toremifene vs tamoxifen. Oncology (Williston Park) 11: 23-28, 1997.
13. Holli K, Valavaara R, Blanco G, Kataja V, Hietanen P, Flander M, Pukkala E and Joensuu H: Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. J Clin Oncol 18: 3487-3494, 2000.
14. Iino Y, Takai Y, Ando T, Sugamata N, Maemura M, Takeo T, Ohwada S and Morishita Y: Effect of toremifene on the growth, hormone receptors and insulin-like growth factor-1 of hormone-dependent MCF-7 tumors in athymic mice. Cancer Chemother Pharmacol 32: 353-358, 1993.
15. Ruohola JK, Valve EM, Karkkainen MJ, Joukov V, Alitalo K and Harkonen PL: Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol 149: 29-40, 1999.
16. Stenbygaard LE, Herrstedt J, Thomsen JF, Svendsen KR, Engelholm SA and Dombernowsky P: Toremifene and tamoxifen in advanced breast cancer - a double-blind cross-over trial. Breast Cancer Res Treat 25: 57-63, 1993.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
18. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, et al: American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28: 3784-3796, 2010.
19. Yamamoto Y, Masuda N, Ohtake T, Yamashita H, Saji S, Kimijima I, Kasahara Y, Ishikawa T, Sawaki M, Hozumi Y and Iwase H: Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor. Breast Cancer 17: 254-260, 2010.
20. Jonsson PE, Malmberg M, Bergljung L, Ingvar C, Ericsson M, Ryden S, Nilsson I and Terje IJ: Phase II study of high dose toremifene in advanced breast cancer progressing during tamoxifene treatment. Anticancer Res 11: 873-875, 1991.
21. Vogel CL, Shemano I, Schoenfelder J, Gams RA and Green MR: Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J Clin Oncol 11: 345-350, 1993.
22. Pyrhonen S, Valavaara R, Vuorinen J and Hajba A: High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment. Breast Cancer Res Treat 29: 223-228, 1994.
23. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, et al: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27: 5529-5537, 2009.
24. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, et al: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491-1494, 1995.